García-Cadenas I, et al. - Via this multicenter, retrospective analysis, researchers estimated the frequency and management of post-transplant lymphoproliferative disorder (PTLD) in Spain. They also focused on prognostic factors affecting outcomes. In 14 transplant units, allogeneic stem cell transplant performed over a 15-year period were analyzed. The estimated frequency of PTLD was 0.8%. The factors that were found to be related to worse overall survival were age ≥ 40 years, malignant underlying disease, non-response to rituximab, and severe thrombocytopenia or lymphocytopenia at PTLD diagnosis. Overall, PTLD was diagnosed in only a small proportion of allografted patients and displayed a highly aggressive clinical course and a poor prognosis which was particularly seen in those failing rituximab.